Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE Trial
NCT05787574Phase 2Recruiting
- Sponsor
- Joseph Oved
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in primary immune regulatory disorder (PIRD), autoinflammatory disease (AID), sponsored by Joseph Oved. Started Mar 2023; status: recruiting.
02
Drugs
emapalumab
03
Conditions
primary immune regulatory disorder (PIRD)autoinflammatory disease (AID)
Beyond the preview
Go deeper on NCT05787574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787574.